Second-line treatment for advanced bile duct and gallbladder cancers
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of liposomal irinotecan with other drugs for people with advanced biliary tract cancer (including bile duct and gallbladder cancers) whose first treatment stopped working. It aims to see if this new approach can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bile duct or gallbladder cancer that got worse after first-line treatment
- You have at least one tumor that can be measured on a scan
- Your overall health is good (ECOG score 0 or 1, meaning you can do daily activities)
- Your vital organs (like liver, kidneys, bone marrow) are working well enough
- You haven't had irinotecan, 5-FU, or antiangiogenic drugs before
- You do not have active heart disease, uncontrolled high blood pressure, or serious stomach/intestinal problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
This trial tests a combination of a cancer-fighting virus (H101), a targeted therapy (lenvatinib), and an immunotherapy (toripalimab) against a standard chemotherapy (FOLFOX) for people with advanced biliary tract cancer that has progressed after one prior treatment. The goal is to see if the new combination is more effective.
This trial tests a combination of radiation therapy (SBRT), two chemotherapy drugs (gemcitabine and cisplatin), and an immunotherapy drug (sintilimab) as a first-line treatment for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether matching targeted therapy to the genetic changes in your cancer can lower the chance of it coming back after surgery. You would first have your tumor tested for specific alterations, and if one is found, you may receive a drug that targets it.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.